Merck KGaA, Darmstadt, Germany: all 522 studies
Page 6 of 6. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- Efalizumab for Treatment of Patients With Moderate to Severe PsoriasisCompletedNCT00442650Phase 3
- Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.WithdrawnNCT00408967Phase 2
- ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone DeficiencyCompletedNCT00407472Phase 1
- RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment OptimizationTerminatedNCT00402818
- AS703569 Phase I in Patients With Solid TumoursCompletedNCT00391521Phase 1
- Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaCompletedNCT00314288Phase 2
- Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's DiseaseTerminatedNCT00304252Phase 2
- Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative ColitisCompletedNCT00303381Phase 2
- A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian StimulationCompletedNCT00298025Phase 4
- An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution SyndromeCompletedNCT00294918Phase 2/3
- Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)CompletedNCT00294164Phase 2/3
- A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)CompletedNCT00292266Phase 3
- Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis SubjectsCompletedNCT00292253Phase 3
- CLEAR Study: Clinical Experience Acquired With Raptiva StudyCompletedNCT00256139Phase 3
- A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian SubjectsCompletedNCT00249860Phase 3
- A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation InductionCompletedNCT00230815Phase 3
- EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given CyclophosphamideCompletedNCT00132522Phase 1
- Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric CancerCompletedNCT00113581Phase 1
- Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) SubjectsWithdrawnNCT00101959Phase 4
- Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque PsoriasisTerminatedNCT00090129Phase 3
- A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian CancerCompletedNCT00073541Phase 2
- Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous TreatmentCompletedNCT00016237Phase 1